Blood-spot 17-hydroxyprogesterone daily profiles in infants with congenital adrenal hyperplasia.
To define the optimum blood levels of 17-hydroxyprogesterone, the hormonal effects of glucocorticoid treatment were studied during the neonatal period and infancy in 20 patients with 21-hydroxylase deficiency. Repeated daily profiles of blood spot 17-hydroxyprogesterone were used to monitor therapy and these data were related to serum concentrations of testosterone. A wide fluctuation of blood 17-hydroxyprogesterone levels was observed in patients with a mean daily value higher than 150 nmol/l indicating poor control. Serum testosterone levels decreased into normal range in female patients with blood-spot 17-hydroxy-progesterone levels between 50 and 150 nmol/l. Daily profiles with mean values less than 50 nmol/l showed low magnitude of circadian variation suggesting overtreatment. We conclude that the daily profile of blood-spot 17-hydroxyprogesterone is a practical alternative in hormonal monitoring of infants treated for congenital adrenal hyperplasia.
Sólyom
J
J
2nd Department of Paediatrics, Semmelweis University Medical School, Budapest, Hungary.
Hosszu
E
E
Gács
G
G
D019326:17-alpha-Hydroxyprogesterone; D000312:Adrenal Hyperplasia, Congenital / Q000097:blood* / Q000188:drug therapy; D002940:Circadian Rhythm / Q000502:physiology; D003348:Cortisone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000097:blood*; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D013739:Testosterone / Q000097:blood
D006908:Hydroxyprogesterones; D013739:Testosterone; D019326:17-alpha-Hydroxyprogesterone; D003348:Cortisone